(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 2.9% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Gilead Sciences's revenue in 2025 is $28,754,000,000.On average, 9 Wall Street analysts forecast GILD's revenue for 2025 to be $35,559,388,537,403, with the lowest GILD revenue forecast at $34,773,798,089,226, and the highest GILD revenue forecast at $35,966,839,616,622. On average, 9 Wall Street analysts forecast GILD's revenue for 2026 to be $37,008,899,123,499, with the lowest GILD revenue forecast at $35,864,347,635,719, and the highest GILD revenue forecast at $38,892,157,516,260.
In 2027, GILD is forecast to generate $39,125,703,489,997 in revenue, with the lowest revenue forecast at $37,716,550,833,732 and the highest revenue forecast at $41,608,257,277,482.